Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZ-801 in early Alzheimer's disease in APOE4 carriers
NL-OMON60452Phase 2Completed
- Sponsor
- Alzheon, Inc.
- Start
- Nov 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of valiltramiprosate in Alzheimer's disease (AD) (2 cohorts), sponsored by Alzheon, Inc. Primary endpoints: Change from baseline to Week 104 in plasma p-tau181, Change from baseline to Week 104 in hippocampal volume on volumetric MRI and 4 more. Started Nov 2020; status: completed.
02
Drugs
valiltramiprosate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60452.